OTCMKTS:BCDA - BioCardia Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.42 -0.01 (-0.70 %) (As of 07/22/2018 04:00 PM ET)Previous Close$1.42Today's Range$1.42 - $1.4552-Week Range$1.26 - $7.74Volume1,600 shsAverage Volume4,489 shsMarket Capitalization$54.35 millionP/E RatioN/ADividend YieldN/ABeta1.9 Company ProfileEarnings HistoryInsider TradesHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System that is in Phase III pivotal trials for the treatment of heart failure and chronic myocardial ischemia. The CardiAMP Cell Therapy System comprises cell potency screening test, a point of care cell processing platform, and a bio-therapeutic delivery system. The company is also developing CardiALLO Cell Therapy System, an allogeneic off the shelf mesenchymal stem cell product candidate, which is in Phase II trials for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California. Receive BCDA News and Ratings via Email Sign-up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolOTCMKTS:BCDA CUSIPN/A Webwww.biocardia.com Phone650-226-0120 Debt Debt-to-Equity RatioN/A Current Ratio4.81 Quick Ratio4.75 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$480,000.00 Price / Sales113.25 Cash FlowN/A Price / CashN/A Book Value$0.29 per share Price / Book4.90 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-12,300,000.00 Net Margins-2,405.73% Return on Equity-105.86% Return on Assets-90.46% Miscellaneous Employees24 Outstanding Shares38,280,000Market Cap$54.35 BioCardia (OTCMKTS:BCDA) Frequently Asked Questions What is BioCardia's stock symbol? BioCardia trades on the OTCMKTS under the ticker symbol "BCDA." How were BioCardia's earnings last quarter? BioCardia Inc (OTCMKTS:BCDA) announced its quarterly earnings data on Friday, May, 11th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.20 million for the quarter. BioCardia had a negative net margin of 2,405.73% and a negative return on equity of 105.86%. View BioCardia's Earnings History. What is the consensus analysts' recommendation for BioCardia? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of BioCardia's key competitors? Some companies that are related to BioCardia include Krystal Biotech (KRYS), Idera Pharmaceuticals (IDRA), Compugen (CGEN), Fennec Pharmaceuticals (FENC), Pluristem Therapeutics (PSTI), Organovo (ONVO), Cidara Therapeutics (CDTX), Eiger Biopharmaceuticals (EIGR), Aptose Biosciences (APTO), Champions Oncology (CSBR), Brainstorm Cell Therapeutics (BCLI), Applied Genetic Technologies (AGTC), Entera Bio (ENTX), Genocea Biosciences (GNCA) and Curis (CRIS). Who are BioCardia's key executives? BioCardia's management team includes the folowing people: Dr. Peter A. Altman, Chief Exec. Officer, Pres and Director (Age 51)Dr. Eric Henricus J. Duckers M.D., Ph.D., FESC, FACC, Chief Medical Officer (Age 50)Mr. Richard Thomas Allen, VP of Quality Assurance (Age 62)Mr. David McClung, Chief Financial Officer (Age 55)Mr. Phil Pesta, VP of Operations (Age 52) Has BioCardia been receiving favorable news coverage? Media coverage about BCDA stock has trended somewhat positive this week, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioCardia earned a media sentiment score of 0.09 on Accern's scale. They also assigned headlines about the company an impact score of 45.92 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. How do I buy shares of BioCardia? Shares of BCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioCardia's stock price today? One share of BCDA stock can currently be purchased for approximately $1.42. How big of a company is BioCardia? BioCardia has a market capitalization of $54.35 million and generates $480,000.00 in revenue each year. BioCardia employs 24 workers across the globe. How can I contact BioCardia? BioCardia's mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company can be reached via phone at 650-226-0120 or via email at [email protected] MarketBeat Community Rating for BioCardia (OTCMKTS BCDA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 13 (Vote Outperform)Underperform Votes: 14 (Vote Underperform)Total Votes: 27MarketBeat's community ratings are surveys of what our community members think about BioCardia and other stocks. Vote "Outperform" if you believe BCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCDA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?